FindTrial
Sign In

Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze

DRUG3 trials

Sponsors

Pfizer Inc., F. Hoffmann-La Roche AG

Conditions

Advanced Breast CancerBreast CancerMetastatic breast cancerOvarian CancerSCLC (Part 1 also had TNBC and NSCLC)and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)hormone receptor positive breast cancer (HR+ BC)including triple negative breast cancer (TNBC)

Phase 1

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC)
RecruitingCTIS2023-503629-20-00
F. Hoffmann-La Roche AGand HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC), hormone receptor positive breast cancer (HR+ BC), including triple negative breast cancer (TNBC) +1
Start: 2018-06-27Target: 50Updated: 2025-08-14
C4161001: PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Active, not recruitingCTIS2024-515492-34-00
Pfizer Inc.Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)
Start: 2023-03-30Target: 12Updated: 2025-11-22

Phase 3

C4891001 - A Phase 3, Randomized, Open-Label, Multicenter Trial Of Arv-471 (PF-07850327) vs Fulvestrant In participants With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment For Advanced Disease (VERITAC-2)
RecruitingCTIS2022-500544-38-00
Pfizer Inc.Advanced Breast Cancer
Start: 2023-06-05Target: 280Updated: 2025-10-10